High-dose intensity modulated radiation therapy for prostate cancer

Current Urology Reports

Volumn 5, Issue 3, 2004, Pages 197-202

  Kuban, Deborah A ^a   Dong, Lei ^b  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b NONE

Author keywords

Intensity Modulate Radiation Therapy; Normal Tissue Complication Probability; Prostate Cancer; Radiat Oncol Biol Phys; Radiation Therapy Oncology Group

Indexed keywords

COMPUTER ASSISTED RADIOTHERAPY; HUMAN; MALE; METHODOLOGY; PROSTATE TUMOR; RADIATION DOSE; REVIEW; TREATMENT OUTCOME;

HUMANS; MALE; PROSTATIC NEOPLASMS; RADIOTHERAPY DOSAGE; RADIOTHERAPY, CONFORMAL; TREATMENT OUTCOME;

EID: 4344625386     PISSN: 15272737     EISSN: 15346285     Source Type: Journal    
DOI: 10.1007/s11934-004-0037-3     Document Type: Article

References (19)

1. Zelefsky MJ, Fuks Z, Hunt M, et al.: High-dose radiation delivered by modulated conformal radiotherapy improves the outcome of intensity localized prostate cancer. J Urol 2001, 166:876–881. Disease-free outcome versus associated toxicity related to using higher versus lower radiation doses with 3D-CRT and IMRT for prostate cancer. DOI: 10.1016/S0022-5347(05)65855-7
2. Zelefsky MJ, Fuks Z, Hunt M, et al.: High-dose intensity modulated radiation therapy for prostate cancer: early toxicity and biochemical outcome in 772 patients. Int J Radiat Oncol Biol Phys 2002, 53:1111–1116. The first published study with a large group of patients (772) using doses as high as 86 Gy with IMRT for prostate cancer. Disease-free outcome and toxicity are reported. DOI: 10.1016/S0360-3016(02)02857-2
3. Chandra A, Dong L, Huang E, et al.: Experience of ultrasoundbased daily prostate localization. Int J Radiat Oncol Biol Phys 2003, 56:436–447. A study pointing out the necessity of daily prostate localization because of the predicted prostate movement outside of the small normal tissue margins necessary for 3D-CRT and IMRT. DOI: 10.1016/S0360-3016(02)04612-6
4. Hanks GE, Martz KL, Diamond JJ: The effect of dose on local control of prostate cancer. Int J Radiat Oncol Biol Phys 1988, 15:1299–1305.
5. Hanks Ge, Hanlon AL, Epstein B, Horwitz EM: Dose response in prostate cancer with 8–12 years follow-up. Int J Radiat Oncol Biol Phys 2002, 54:427–435. DOI: 10.1016/S0360-3016(02)02954-1
6. Lyons JA, Kupelian PA, Mohan DS, et al.: Importance of high radiation doses (72 Gy or greater) in the treatment of Stage T1-T3 adenocarcinoma of the prostate. Urology 2000, 55:85–90. DOI: 10.1016/S0090-4295(99)00380-5
7. Pollack A, Zagars GK, Starkschall G, et al.: Prostate cancer radiation dose response: results of the M.D. Anderson phase III randomized trial. Int J Radiat Oncol Biol Phys 2002, 53:1097–1105. The only randomized dose-escalation study for prostate cancer. Disease-free outcome and toxicity are reported. DOI: 10.1016/S0360-3016(02)02829-8
8. Kuban DA, Thames HD, Levy LB, et al.: Long-term multi-institutional analysis of Stage T1-T2 prostate cancer treated with radiotherapy in the PSA era. Int J Radiat Oncol Biol Phys 2003, 57:915–928. A long-term multi-institutional outcome study of 4839 patients with stage T1-T2 prostate cancer treated with radiation alone from 1987–1995. The dose analysis has implications for IMRT. DOI: 10.1016/S0360-3016(03)00632-1
9. Kuban D, Pollack A, Huang E, et al.: Hazards of dose escalation in prostate cancer radiotherapy. Int J Radiat Oncol Biol Phys 2003, 57:1260–1268. DOI: 10.1016/S0360-3016(03)00772-7
10. Kupelian PA, Kuban D, Thames H, et al.: Improved biochemical relapse-free survival with increased external radiation doses in patients with localized prostate cancer: the combined experience of nine institutions in patients treated in 1994 and 1995. Int J Radiat Oncol Biol Phys 2003, 57:S271-S272. DOI: 10.1016/S0360-3016(03)00630-8
11. Zelefsky MJ, Fuks Z, Chan H, et al.: Ten-year results of dose escalation with 3-dimensional conformal radiotherapy for patients with clinically localized prostate cancer. Int J Radiat Oncol Biol Phys 2003, 57:S149.
12. Chism DB, Horwitz EM, Hanlon AL, et al.: Late morbidity profiles in prostate cancer patients treated to 79-84 Gy by a simple four-field coplanar beam arrangement. Int J Radiat Oncol Biol Phys 2003, 55:71–77. DOI: 10.1016/S0360-3016(02)03822-1
13. Storey MR, Pollack A, Zagars G, et al.: Complications from radiotherapy dose escalation in prostate cancer: preliminary results of a randomized trial. Int J Radiat Oncol Biol Phys 2000, 48:635–642. DOI: 10.1016/S0360-3016(00)00700-8
14. Huang EH, Pollack A, Levy L, et al.: Late rectal toxicity: dosevolume effects of conformal radiotherapy for prostate cancer. Int J Radiat Oncol Biol Phys 2002, 54:1314–1321. A thorough analysis of rectal complication rates associated with increasing dose in prostate cancer radiation and parameters to minimize toxicity. DOI: 10.1016/S0360-3016(02)03742-2
15. Cheung R, Tucker LS, Ye JS, et al.: Characterization of rectal normal tissue complication probability after high-dose external beam radiotherapy for prostate cancer. Int J Radiat Oncol Biol Phys 2003, in press.
16. Michalski J, Winter K, Purdy JA, et al.: Toxicity following 3D radiation therapy for prostate cancer on RTOG 9406 dose level V. Int J Radiat Oncol Biol Phys 2003, 57:S151.
17. Michalski JF, Winter K, Purdy JA, et al.: Preliminary evaluation of low-grade toxicity with conformal radiation therapy for prostate cancer on RTOG 9406 dose levels I and II. Int J Radiat Oncol Biol Phys 2003, 56:192–198. Analysis of the Radiation Therapy Oncology Group dose escalation study with regard to grade-2 versus grade-3 complication rates. DOI: 10.1016/S0360-3016(03)00072-5
18. Michalski JM, Purdy JA, Winter K, et al.: Preliminary report of toxicity following 3D radiation therapy for prostate cancer on 3DOG/RTOG 9406. Int J Radiat Oncol Biol Phys 2000, 46:391–402. DOI: 10.1016/S0360-3016(99)00443-5
19. Gardner BG, Zietman AL, Shipley WU, et al.: Late normal tissue sequelae in the second decade after high dose radiation therapy with combined photons and conformal protons for locally advanced prostate cancer. J Urol 2002, 167:123–126. DOI: 10.1016/S0022-5347(05)65395-5